Q-omics provides the consensus-scored MBOAT4 profile across patient tissues and cancer cell-line models. MBOAT4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MBOAT4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MBOAT4 RNA expression shows 17,247 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, KIRC, and ACC as cancer lineages where MBOAT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBOAT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBOAT4 survival associations across molecular data types. MBOAT4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBOAT4 RNA expression–survival associations across cancer types. High MBOAT4 expression shows unfavorable associations in STAD, LIHC, KIRP and LGG, but favorable associations in SKCM and HNSC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MBOAT4 RNA expression.
This table summarizes MBOAT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MBOAT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBOAT4 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, KIRP, HNSC and CHOL. The KIRC box plot shows higher MBOAT4 RNA expression in tumor versus normal tissue (log2 FC = +0.793, t-test p < 0.001).
This table shows molecular features associated with MBOAT4 in patient tissues and cancer cell lines. In patient samples, MBOAT4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBOAT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
